Compare Ecolab Inc. (ECL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs TG Therapeutics Inc — how do they compare? Ecolab Inc. trades at $278.45 (market cap $79.79B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Ecolab Inc. is far larger — about 10.4× TG Therapeutics Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ECL | TGTX | |
|---|---|---|
Market Cap | $79.79B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $59.06 |
52-Week Low | $245.73 | $26.94 |
Enterprise Value | $88.57B | $7.84B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecolab Inc. (ECL) trades at $278.02, down 2.24% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.09 versus $2.08 expected, driven by 5% organic sales growth. Recent acquisition of CoolIT for $4.75 billion strengthens its AI cooling portfolio. Valuation ratios are elevated, with a P/E of 38.21 and P/S of 4.8, reflecting premium pricing for its consistent profitability and market position.
The outlook remains positive with a consensus price target of $327.90, implying 18% upside, supported by 78% analyst buy ratings. Key risks include high valuation sensitivity to earnings misses, as seen in Q1 2026, and rising input costs pressuring margins. Long-term growth is underpinned by digital expansion and high-tech segment strength, but investors should monitor execution on guidance and macroeconomic pressures on industrial demand.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
